Corvus Pharmaceuticals CRVS
NASDAQ CRVS
$10.93 -0.59 (-5.12%)
At close: Oct 1, 2026 · 4:00 PM EDT

Corvus Pharmaceuticals (CRVS) Preferred Stock Liabilities (2015)

Updated

Corvus Pharmaceuticals (CRVS) posted Preferred Stock Liabilities of $125.78 million for Q4 2015.

Analysis

Corvus Pharmaceuticals (CRVS) Preferred Stock Liabilities (2015) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn -
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn -
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn -
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn -
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn -
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn -
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn -
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn -
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn -
10 Corvus Pharmaceuticals 969.07 Mn 457.51 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2015 125.78 Mn
API Access

Corvus Pharmaceuticals Preferred Stock Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=preferred-stock-liabilities&ticker=CRVS&period=max&api_key=YOUR_API_KEY